What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo?

Featuring David Rosmarin, MD |

Vice Chair of Education and Research
Tufts Medical Center
Boston, MA

| Published May 01, 2024